AC Immune (ACIU) Competitors $2.12 -0.08 (-3.64%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$2.12 0.00 (0.00%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACIU vs. AVBP, IMNM, PHAR, CMRX, CDMO, GYRE, COGT, REPL, CRON, and VIRShould you be buying AC Immune stock or one of its competitors? The main competitors of AC Immune include ArriVent BioPharma (AVBP), Immunome (IMNM), Pharming Group (PHAR), Chimerix (CMRX), Avid Bioservices (CDMO), Gyre Therapeutics (GYRE), Cogent Biosciences (COGT), Replimune Group (REPL), Cronos Group (CRON), and Vir Biotechnology (VIR). These companies are all part of the "pharmaceutical products" industry. AC Immune vs. Its Competitors ArriVent BioPharma Immunome Pharming Group Chimerix Avid Bioservices Gyre Therapeutics Cogent Biosciences Replimune Group Cronos Group Vir Biotechnology AC Immune (NASDAQ:ACIU) and ArriVent BioPharma (NASDAQ:AVBP) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, community ranking, media sentiment, analyst recommendations, dividends and profitability. Does the MarketBeat Community prefer ACIU or AVBP? AC Immune received 239 more outperform votes than ArriVent BioPharma when rated by MarketBeat users. However, 95.83% of users gave ArriVent BioPharma an outperform vote while only 62.68% of users gave AC Immune an outperform vote. CompanyUnderperformOutperformAC ImmuneOutperform Votes26262.68% Underperform Votes15637.32% ArriVent BioPharmaOutperform Votes2395.83% Underperform Votes14.17% Which has more risk and volatility, ACIU or AVBP? AC Immune has a beta of 1.57, suggesting that its stock price is 57% more volatile than the S&P 500. Comparatively, ArriVent BioPharma has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Which has better earnings & valuation, ACIU or AVBP? AC Immune has higher revenue and earnings than ArriVent BioPharma. ArriVent BioPharma is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAC Immune$28.30M7.52-$60.41M-$0.58-3.66ArriVent BioPharmaN/AN/A-$69.33M-$3.77-6.18 Is ACIU or AVBP more profitable? AC Immune's return on equity of -28.26% beat ArriVent BioPharma's return on equity.Company Net Margins Return on Equity Return on Assets AC ImmuneN/A -28.26% -18.98% ArriVent BioPharma N/A -43.89%-29.67% Do analysts rate ACIU or AVBP? AC Immune currently has a consensus price target of $12.00, indicating a potential upside of 466.04%. ArriVent BioPharma has a consensus price target of $39.29, indicating a potential upside of 68.75%. Given AC Immune's higher possible upside, equities research analysts clearly believe AC Immune is more favorable than ArriVent BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AC Immune 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00ArriVent BioPharma 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Does the media prefer ACIU or AVBP? In the previous week, ArriVent BioPharma had 4 more articles in the media than AC Immune. MarketBeat recorded 5 mentions for ArriVent BioPharma and 1 mentions for AC Immune. AC Immune's average media sentiment score of 1.89 beat ArriVent BioPharma's score of 1.12 indicating that AC Immune is being referred to more favorably in the media. Company Overall Sentiment AC Immune Very Positive ArriVent BioPharma Positive Do institutionals & insiders have more ownership in ACIU or AVBP? 51.4% of AC Immune shares are owned by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are owned by institutional investors. 4.6% of AC Immune shares are owned by insiders. Comparatively, 18.6% of ArriVent BioPharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummaryAC Immune beats ArriVent BioPharma on 11 of the 17 factors compared between the two stocks. Get AC Immune News Delivered to You Automatically Sign up to receive the latest news and ratings for ACIU and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACIU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACIU vs. The Competition Export to ExcelMetricAC ImmunePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$212.87M$6.85B$5.57B$8.62BDividend YieldN/A2.56%5.28%4.18%P/E Ratio-4.618.7827.1720.06Price / Sales7.52255.64410.88157.10Price / CashN/A65.8538.2534.64Price / Book1.006.557.094.70Net Income-$60.41M$143.93M$3.23B$247.88M7 Day Performance22.54%3.97%2.91%2.66%1 Month Performance30.06%11.32%9.09%6.40%1 Year Performance-54.31%4.20%31.75%14.07% AC Immune Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACIUAC Immune2.6472 of 5 stars$2.12-3.6%$12.00+466.0%-52.7%$212.87M$28.30M-4.61140Positive NewsAVBPArriVent BioPharma1.4586 of 5 stars$23.60+0.3%$39.29+66.5%+24.4%$807.43MN/A-6.2640Positive NewsIMNMImmunome1.7742 of 5 stars$9.27+1.5%$23.33+151.7%-39.6%$806.60M$10.94M-1.1440Positive NewsPHARPharming Group2.0556 of 5 stars$11.81-0.4%$30.00+154.0%+32.9%$803.45M$320.71M-45.42280News CoverageShort Interest ↑Gap UpCMRXChimerix0.6843 of 5 stars$8.54flat$8.53-0.1%N/A$801.09M$212K-9.0990CDMOAvid Bioservices0.8619 of 5 stars$12.50+0.1%$12.25-2.0%+56.4%$799.18M$139.91M-5.23320High Trading VolumeGYREGyre Therapeutics0.3466 of 5 stars$8.50+1.1%N/A-21.8%$796.94M$100.64M425.0040Short Interest ↓COGTCogent Biosciences2.487 of 5 stars$6.90+1.5%$14.57+111.2%-17.7%$785.61MN/A-2.7880Positive NewsREPLReplimune Group4.5049 of 5 stars$10.18-1.9%$20.83+104.6%+8.7%$784.75MN/A-3.32210Positive NewsCRONCronos Group1.702 of 5 stars$1.96-1.0%N/A-21.0%$755.94M$124.59M-15.08450Positive NewsVIRVir Biotechnology3.0632 of 5 stars$5.43-0.4%$32.86+505.1%-50.6%$750.63M$14.30M-1.39580Positive News Related Companies and Tools Related Companies ArriVent BioPharma Competitors Immunome Competitors Pharming Group Competitors Chimerix Competitors Avid Bioservices Competitors Gyre Therapeutics Competitors Cogent Biosciences Competitors Replimune Group Competitors Cronos Group Competitors Vir Biotechnology Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACIU) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump Makes Major Crypto AnnouncementPay close attention to what I'm about to share… Most investors think Trump's pro-crypto policies will lift ...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMarch 16th -- America’s most important day?50-Year Legend: Here's The Day Stocks Likely Crash Legendary quant analyst Marc Chaikin says in 50 years on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AC Immune SA Please log in to your account or sign up in order to add this asset to your watchlist. Share AC Immune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ACIU Stock Free ACIU Stock Alerts